AstraZeneca PLC [AZN] Is Currently 1.11 below its 200 Period Moving Avg: What Does This Mean?


AstraZeneca PLC [NASDAQ: AZN] gained 1.11% or 0.74 points to close at $67.17 with a heavy trading volume of 7273318 shares. The company report on April 28, 2022 that ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


First and only long-acting C5 complement inhibitor to demonstrate clinical improvement in patients with generalized myasthenia gravis.

ULTOMIRIS showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks.

It opened the trading session at $66.49, the shares rose to $67.272 and dropped to $66.49, the range by which the price of stock traded the whole day. The daily chart for AZN points out that the company has recorded 7.54% gains over the past six months. However, it is still -27.36% lower than its most recent low trading price.

If we look at the average trading volume of 8.07M shares, AZN reached to a volume of 7273318 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about AstraZeneca PLC [AZN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $72.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

DZ Bank have made an estimate for AstraZeneca PLC shares, keeping their opinion on the stock as Hold, with their previous recommendation back on February 11, 2022. The new note on the price target was released on December 07, 2021, representing the official price target for AstraZeneca PLC stock.

The Average True Range (ATR) for AstraZeneca PLC is set at 1.33, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 5.55. The Price to Book ratio for the last quarter was 5.30, with the Price to Cash per share for the same quarter was set at 2.07. Price to Free Cash Flow for AZN in the course of the last twelve months was 204.46 with Quick ratio for the last quarter at 0.80.

Trading performance analysis for AZN stock

AstraZeneca PLC [AZN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.24. With this latest performance, AZN shares gained by 0.54% in over the last four-week period, additionally plugging by 7.54% over the last 6 months – not to mention a rise of 26.90% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 53.23, with the RSI for the last a single of trading hit 51.84, and the three-weeks RSI is set at 54.74 for AstraZeneca PLC [AZN]. The present Moving Average for the last 50 days of trading for this stock 64.56, while it was recorded at 66.68 for the last single week of trading, and 59.95 for the last 200 days.

AstraZeneca PLC [AZN]: A deeper dive into fundamental analysis

AstraZeneca PLC’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.20.

AstraZeneca PLC [AZN]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AstraZeneca PLC go to 15.40%.

An analysis of insider ownership at AstraZeneca PLC [AZN]

There are presently around $33,575 million, or 17.40% of AZN stock, in the hands of institutional investors. The top three institutional holders of AZN stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 89,840,751, which is approximately 9.133% of the company’s market cap and around 0.50% of the total institutional ownership; WELLINGTON MANAGEMENT GROUP LLP, holding 47,105,051 shares of the stock with an approximate value of $3.13 billion in AZN stocks shares; and PRIMECAP MANAGEMENT CO/CA/, currently with $3.1 billion in AZN stock with ownership of nearly -3.265% of the company’s market capitalization.

Positions in AstraZeneca PLC stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 412 institutional holders increased their position in AstraZeneca PLC [NASDAQ:AZN] by around 36,740,396 shares. Additionally, 406 investors decreased positions by around 49,676,603 shares, while 218 investors held positions by with 419,009,565 shares. The mentioned changes placed institutional holdings at 505,426,564 shares, according to the latest SEC report filing. AZN stock had 125 new institutional investments in for a total of 5,847,718 shares, while 90 institutional investors sold positions of 8,884,045 shares during the same period.